Physician profile
Lars Gjerde
NPI 1912411687
$3,075.49
in general payments reported to CMS, 2019-2025
21 companies · $751 in 2025
The $751 reported for 2025 was more than what 83% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $339 · 2022: $609 · 2023: $1,143 · 2024: $234 · 2025: $751.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,128.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $346.28 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $245.19 | 2021-2025 | Tezspire |
| Abbott Laboratories | $232.61 | 2023 | Freestyle Libre 3, Thoratec Heartmate 3 Lvas Implant Kit |
| Teva Pharmaceuticals USA, INC. | $221.49 | 2022-2025 | |
| Abbvie INC. | $219.27 | 2022-2023 | |
| Supernus Pharmaceuticals, INC. | $145.35 | 2021 | |
| Medtronic, INC. | $144.78 | 2023 | Intellis Adaptivestim |
| Spr Therapeutics, INC | $133.18 | 2025 | Sprint Pns System |
| Incyte Corporation | $130.82 | 2025 | |
| Amylyx Pharmaceuticals, INC. | $121.87 | 2023 | Relyvrio |
| Alnylam Pharmaceuticals INC. | $121.86 | 2024 | Amvuttra |
| Neurocrine Biosciences, INC. | $121.37 | 2025 | |
| Averitas Pharma INC. | $121.09 | 2023 | Qutenza |
| Cvrx, INC. | $116.76 | 2022 | |
| Gilead Sciences, INC. | $112.61 | 2024 | Biktarvy |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $103.99 | 2023 | Afrezza |
| Exact Sciences Corporation | $98.13 | 2023 | Cologuard Collection Kit |
| Biogen, INC. | $94.48 | 2022 | |
| Scynexis, INC. | $92.05 | 2022 | |
| Janssen Pharmaceuticals, INC | $81.04 | 2023 | Spravato |
| Gen-Probe Sales & Service, INC. | $71.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lars Gjerde listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.